Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 57

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 57
---
 Investors exercise all 20,076,500 Pre-Funded Warrants issued in the PIPE Financing, the
securities issued in the PIPE Financing will account for approximately 63% of the total shares outstanding at that time (based on 24,696,568 total shares outstanding as of January 30, 2025 and after giving effect to the 21,592,000 shares
expected to be issued in the PIPE Financing and 20,076,500 shares that would be issued pursuant to exercise of the Pre-Funded Warrants).As a result, stockholders who did not participate in the PIPE Financing will experience substantial
dilution upon closing of the PIPE Financing, if approved by stockholders.

If the PIPE Financing Proposal is approved and the PIPE Offering is completed, a substantial number of shares of common stock will be restricted from immediate resale but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.

Following the consummation of the PIPE Financing, all of the shares of common stock and the shares underlying the Pre-Funded
Warrants will be restricted securities and will not be immediately available for resale. Once we register these shares pursuant to the Registration Rights Agreement, however, they can be freely sold in the public market. As these securities are
registered for resale, the market price of our stock could decline if the holders of currently restricted shares of common stock sell them or are perceived by the market as intending to sell them.

The sale by the PIPE Investors of a significant number of shares of common stock could have a significant negative impact on the market price of our common
stock. In addition, the perception in the public markets that the PIPE Investors may sell all or a portion of the shares issued in the PIPE Financing as a result of the registration of such shares for resale pursuant to the Registration Rights
Agreement could also in and of itself have a material adverse effect on the market price of our common stock. We cannot predict the effect, if any, that market sales of those shares or the availability of those shares for resale will have on the
market price of our common stock. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock.

We may become obligated to pay liquidated damages if we fail to file, obtain effectiveness and maintain effectiveness of the resale registration statement in accordance with the terms of the